Halozyme To Release Important Data This Coming Monday Print E-mail
By Scott Matsow   
Thursday, 26 September 2013 09:59

StockMatusow's  best small cap Biopharma pick, Halozyme, (NASDAQ: HALO) will present its full data on PEGPH20 at a Poster Presentation at ECCO-ESMO-ESTRO on September 30th, 2013.

 

 
  • "A Phase 1b study of gemcitabine plus PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer" will be presented by Joy Zhu M.D., Ph.D., Vice President, Oncology Clinical Development, Halozyme on Monday, September 30 in Hall 4 at 14:00 CEST. (Abstract #2598)


A Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 in combination with nab-paclitaxel and gemcitabine for the treatment of stage IV pancreatic cancer began in April 2013. Approximately 124 patients are expected to participate in the trial and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Halozyme is also developing an HA diagnostic tool for use in the Phase 2 study to evaluate potential treatment benefit based on tumor HA levels. This HA-diagnostic approach may also enable the testing of PEGPH20 in other HA-rich tumor types.
The above data is for Halozyme's propreitary PEGPH20, which if ultimately sucessfull, could net the company billions in the years ahead, and could end up to be a new standard of care, in terms of platform technology.


Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

In most patients diagnosed with metastatic pancreatic adenocarcinoma, survival rates are the lowest of any cancer. In 2013, it is estimated that almost 45,000 new cases of pancreatic cancer will be diagnosed. About one-in-78 people in the U.S. will develop the disease, affecting equal numbers of men and women, almost always after the age of 45. Its tendency to spread prior to diagnosis makes it the fourth deadliest cancer with a less than six percent five-year relative survival rate, with more than 38,000 people succumbing to the disease each year.Halozyme is StockMatusow's best small cap investment pick of this year as we feel a stock price over $20 in the next year is likely, and potentially over $50 in the next 3 years or so.


The below chart shows that Halo is about to break out on the 60 minute chart, We see a MACD cross setting up and strong signal, along with wedge continuation from decension. Target price for this trade is over $11.
 

Accumulation has been very good, and sentiment is strong. I was informed the other day that a well-known Biotech Investor recently bought $2M shares and he believes the stock will hit over $50 in  2 years. Needless to say, Halo is StockMatusow’s best Longer term Speculative investment, and makes for excellent trading because of good liquidity.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter